Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin-Reference-Cited by-同舟云学术

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin

Published:2021-05-01 Issue:5 Volume:181 Page:598
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Bradley Marie C.¹,Chillarige Yoganand²,Lee Hana³,Wu Xiyuan²,Parulekar Shruti²,Muthuri Stella²,Wernecke Michael²,MaCurdy Thomas E.²,Kelman Jeffrey A.⁴,Graham David J.¹

Affiliation:

1. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

2. Acumen LLC, Burlingame, California

3. Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland

4. Centers for Medicare & Medicaid Services, Washington, DC

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2777049/jamainternal_bradley_2021_oi_200118_1619193313.78729.pdf

Reference24 articles.

1. Estimation of Medicare Part D spending on insulin for patients with diabetes using negotiated prices and a defined formulary.;Feldman;JAMA Intern Med,2020

2. Cost-related insulin underuse among patients with diabetes.;Herkert;JAMA Intern Med,2019

3. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.;Horvath;Cochrane Database Syst Rev,2007

4. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.;Eliaschewitz;Arch Med Res,2006

5. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial.;Fritsche;Ann Intern Med,2003

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin therapy in type 2 diabetes: Insights into clinical efficacy, patient-reported outcomes, and adherence challenges;World Journal of Diabetes;2024-05-15

2. Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review;Diabetes Research and Clinical Practice;2024-05

3. Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes;Annals of Internal Medicine;2024-04

4. Frailty in Older People with Diabetes Mellitus;Frailty;2024

5. 13. Older Adults: Standards of Care in Diabetes—2024;Diabetes Care;2023-12-11